statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics ) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

This indicator may be signaling that FATE's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Fate Therapeutics (FATE, $7.09) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have received an average rating of "Hold" from the eleven research firms that are covering the firm, MarketBeat Ratings reports. One...

Analysts Set Fate Therapeutics, Inc. (NASDAQ:FATE) Target Price at $6.80

A month has gone by since the last earnings report for Amicus Therapeutics (FOLD). Shares have lost about 8.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Fate Therapeutics (NASDAQ:FATE  Get Free Report) had its target price boosted by equities research analysts at Bank of America from $2.00 to $6.00 in a report issued on Thursday, Benzinga...

Fate Therapeutics (NASDAQ:FATE) Price Target Raised to $6.00 at Bank of America

It has been about a month since the last earnings report for Myriad Genetics (MYGN). Shares have lost about 1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

Fate Therapeutics (FATE, $7.44) entered Downtrend as Momentum indicator drops below 0 level on Mar 20, 2024

Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement...

Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement

Fate Therapeutics, Inc. (NASDAQ:FATE  Get Free Report) shares were down 6.9% during mid-day trading on Thursday . The company traded as low as $6.97 and last traded at $7.11. Approximately...

Fate Therapeutics (NASDAQ:FATE)  Shares Down 6.9%

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Volume	4.02M
52-Wk High	$8.83
52-Wk Low	$1.63

FATE Fate Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals